CN115052884B - 单特异性和多特异性抗体 - Google Patents

单特异性和多特异性抗体

Info

Publication number
CN115052884B
CN115052884B CN202080082179.3A CN202080082179A CN115052884B CN 115052884 B CN115052884 B CN 115052884B CN 202080082179 A CN202080082179 A CN 202080082179A CN 115052884 B CN115052884 B CN 115052884B
Authority
CN
China
Prior art keywords
ser
gly
ala
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080082179.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN115052884A (zh
Inventor
梁延斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Shuoxing Biomedical Technology Co ltd
Original Assignee
Beijing Shuoxing Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Shuoxing Biomedical Technology Co ltd filed Critical Beijing Shuoxing Biomedical Technology Co ltd
Publication of CN115052884A publication Critical patent/CN115052884A/zh
Application granted granted Critical
Publication of CN115052884B publication Critical patent/CN115052884B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080082179.3A 2019-09-27 2020-09-28 单特异性和多特异性抗体 Active CN115052884B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962907275P 2019-09-27 2019-09-27
US62/907,275 2019-09-27
US202062989327P 2020-03-13 2020-03-13
US62/989,327 2020-03-13
PCT/US2020/053064 WO2021062361A2 (en) 2019-09-27 2020-09-28 Monospecific and multi-specific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610213990.XA Division CN121975011A (en) 2019-09-27 2020-09-28 Monospecific and multispecific antibodies

Publications (2)

Publication Number Publication Date
CN115052884A CN115052884A (zh) 2022-09-13
CN115052884B true CN115052884B (zh) 2026-03-17

Family

ID=75166476

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080082179.3A Active CN115052884B (zh) 2019-09-27 2020-09-28 单特异性和多特异性抗体

Country Status (8)

Country Link
US (1) US20230340157A1 (https=)
EP (1) EP4034549A4 (https=)
JP (1) JP2022549362A (https=)
KR (1) KR20220070249A (https=)
CN (1) CN115052884B (https=)
AU (1) AU2020353182A1 (https=)
CA (1) CA3156160A1 (https=)
WO (1) WO2021062361A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2022109987A1 (en) * 2020-11-27 2022-06-02 Shanghai Benemae Pharmaceutical Corporation Novel anti-lag3 antibodies and methods of making and using the same
WO2023274183A1 (zh) * 2021-06-29 2023-01-05 江苏先声药业有限公司 Cd16抗体及其应用
US20250388669A1 (en) * 2022-01-21 2025-12-25 Jieyi Wang Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation
WO2023224412A1 (ko) * 2022-05-19 2023-11-23 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 인간화 단일 도메인 항체 및 이의 용도
CN119768433A (zh) * 2022-06-28 2025-04-04 珠海烁星生物医药科技有限公司 单特异性和多特异性抗体
CN118255894A (zh) * 2022-12-27 2024-06-28 广东菲鹏制药股份有限公司 一种双特异性结合分子及其应用
WO2025101526A1 (en) * 2023-11-06 2025-05-15 Beijing Starmab Biomed Technology Ltd Multi-specific cancer-targeting antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1735630A (zh) * 2003-01-10 2006-02-15 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
WO2019068302A1 (ru) * 2017-10-03 2019-04-11 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2658869B1 (en) * 2010-12-30 2019-06-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigen binding formats for use in therapeutic treatments or diagnostic assays
KR102100388B1 (ko) * 2012-02-06 2020-04-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
WO2014198748A1 (en) * 2013-06-11 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
PL3560954T3 (pl) * 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
CN104804093A (zh) * 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
CN106432502B (zh) * 2015-08-10 2020-10-27 中山大学 用于治疗cea阳性表达肿瘤的双特异纳米抗体
EP3502142B1 (en) * 2016-06-22 2021-10-27 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Bispecific antibody and antibody conjugate for tumour therapy and use thereof
CN109096395B (zh) * 2017-06-20 2022-06-24 华兰生物工程股份有限公司 阻断型cd47纳米抗体及其用途
EP3724338A4 (en) * 2017-12-14 2021-09-29 Salk Institute for Biological Studies GENETICALLY CODED FLUORESCENT IRON FERRITIN NANOPARTICLE PROBES FOR INTRACELLULAR TARGET DETECTION BY FLUORESCENT AND ELECTRONIC MICROSCOPY
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
CN110003335B (zh) * 2019-04-12 2023-07-04 深圳普瑞金生物药业股份有限公司 Cd47单域抗体、核酸及试剂盒
US20210324477A1 (en) * 2020-04-21 2021-10-21 Grail, Inc. Generating cancer detection panels according to a performance metric
US11791597B2 (en) * 2021-02-05 2023-10-17 Aptiv Technologies (2) S.À R.L. Flexible electrical bus bar and method of manufacturing the same
CN119768433A (zh) * 2022-06-28 2025-04-04 珠海烁星生物医药科技有限公司 单特异性和多特异性抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1735630A (zh) * 2003-01-10 2006-02-15 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
WO2019068302A1 (ru) * 2017-10-03 2019-04-11 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1

Also Published As

Publication number Publication date
AU2020353182A1 (en) 2022-04-14
US20230340157A1 (en) 2023-10-26
JP2022549362A (ja) 2022-11-24
CN115052884A (zh) 2022-09-13
WO2021062361A2 (en) 2021-04-01
CA3156160A1 (en) 2021-04-01
EP4034549A2 (en) 2022-08-03
EP4034549A4 (en) 2024-03-06
KR20220070249A (ko) 2022-05-30
WO2021062361A3 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
CN115052884B (zh) 单特异性和多特异性抗体
JP7143452B2 (ja) ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用
JP6608702B2 (ja) 補体関連疾患の予防及び治療のためのｃ５抗体及び方法
US20220162331A1 (en) Anti-cd73 monoclonal antibody and application thereof
AU2015384281B2 (en) Novel antibody binding to TFPI and composition comprising the same
CN110475570B (zh) 抗人膜联蛋白a1抗体
TW201741340A (zh) Cd47抗體及使用其之方法
WO2021170082A1 (zh) 抗cd47/抗pd-l1抗体及其应用
US20230192861A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
US20220064337A1 (en) Antigen binding formats for receptor complexes
KR102691493B1 (ko) α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도
CN121975011A (en) Monospecific and multispecific antibodies
CN116438198A (zh) 能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体
HK40080982A (en) Monospecific and multispecific antibodies
US20210163614A1 (en) Apj antibody, fusion protein thereof with elabela, and pharmaceutical compositions and use thereof
US20250075002A1 (en) MUC1 and CD16A Antibodies and Methods of Use
WO2025101526A1 (en) Multi-specific cancer-targeting antibodies
KR20250156803A (ko) 항-cd3 다중특이적 항체 및 사용 방법
WO2025101525A1 (en) Monospecific and multi-specific antibodies
KR20250158060A (ko) 항-cldn6 및 항-cd3 다중특이적 항체 및 사용 방법
KR20250130525A (ko) 신규한 항-Ang-2 항체 및 이의 용도
JP2025538110A (ja) ヒトｒｏｒ１を標的とする単一ドメイン抗体
JP2026507191A (ja) Ｍｕｃ１抗体及び使用方法
KR20240022546A (ko) 항il-36r 항체 및 그의 사용
HK40096583A (zh) 能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080982

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant